trending Market Intelligence /marketintelligence/en/news-insights/trending/3mo7IA_zIDGhGR5oH24aIw2 content esgSubNav
In This List

Neurotrope starts strategic review after Alzheimer's drug fails mid-stage study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Neurotrope starts strategic review after Alzheimer's drug fails mid-stage study

Neurotrope Inc. said it plans to explore strategic alternatives to maximize shareholder value after its Alzheimer's disease drug fails to reduce symptoms in a phase 2 study.

Results from the study, which were announced Sept. 9, showed that Bryostatin-1 failed to best the placebo in improving cognitive deficits in patients with Alzheimer's disease.

In an Oct. 8 release, the company's CEO Charles Ryan said a review of strategic alternatives following the results from Neurotrope's drug Bryostatin-1's phase 2 study is an important step in preserving and enhancing shareholder value.

While the New York-based biopharmaceutical Neurotrope continues to determine how to proceed with the drug's development programs, its board has formed a committee to evaluate alternatives that may or may not result in any successful transactions or other outcomes.